First published data from randomized trials using SGLT-2i in the treatment of patients with T1DM came from Canagliflozin and proved beneficial in metabolic control with a decrease in HbA1c and total insulin daily dose with no increased risk of hypoglycemia and decrease in body weight [48,150,151,152,153]. Here, INS is linked to Hypoglycemia.